Nektar Therapeutics (NASDAQ: NKTR) has seen a decline in its stock price by -1.37 in relation to its previous close of 8.73. However, the company has experienced a -9.84% decline in its stock price over the last five trading sessions. seekingalpha.com reported 2025-06-11 that Results from Nektar Therapeutics’ phase 2b REZOLVE-AD study, using REZPEG for the treatment of patients with atopic dermatitis, are expected in June 2025. The global atopic dermatitis treatment market is projected to reach $28.7 billion by 2031. NKTR’s results from phase 2b REZOLVE-AA, using REZPEG for the treatment of patients with Alopecia Areata, expected in the 2nd half of 2025.
Is It Worth Investing in Nektar Therapeutics (NASDAQ: NKTR) Right Now?
Additionally, the 36-month beta value for NKTR is 0.56. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for NKTR is 11.96M and currently, short sellers hold a 6.30% ratio of that float. The average trading volume of NKTR on June 19, 2025 was 205.68K shares.
NKTR’s Market Performance
The stock of Nektar Therapeutics (NKTR) has seen a -9.84% decrease in the past week, with a -17.41% drop in the past month, and a -36.02% fall in the past quarter. The volatility ratio for the week is 5.58%, and the volatility levels for the past 30 days are at 9.30% for NKTR. The simple moving average for the last 20 days is -13.85% for NKTR stock, with a simple moving average of -39.42% for the last 200 days.
Analysts’ Opinion of NKTR
Many brokerage firms have already submitted their reports for NKTR stocks, with Jefferies repeating the rating for NKTR by listing it as a “Buy.” The predicted price for NKTR in the upcoming period, according to Jefferies is $2 based on the research report published on April 11, 2025 of the current year 2025.
Oppenheimer, on the other hand, stated in their research note that they expect to see NKTR reach a price target of $6. The rating they have provided for NKTR stocks is “Outperform” according to the report published on March 14th, 2025.
B. Riley Securities gave a rating of “Buy” to NKTR, setting the target price at $4 in the report published on January 08th of the current year.
NKTR Trading at -13.74% from the 50-Day Moving Average
After a stumble in the market that brought NKTR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -62.22% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NKTR starting from Zalevsky Jonathan, who sale 10,712 shares at the price of $0.67 back on May 19 ’25. After this action, Zalevsky Jonathan now owns 305,892 shares of Nektar Therapeutics, valued at $7,177 using the latest closing price.
Wilson Mark Andrew, the Chief Legal Officer of Nektar Therapeutics, sale 9,996 shares at $0.67 during a trade that took place back on May 19 ’25, which means that Wilson Mark Andrew is holding 314,296 shares at $6,697 based on the most recent closing price.
Stock Fundamentals for NKTR
Current profitability levels for the company are sitting at:
- -1.31 for the present operating margin
- 0.75 for the gross margin
The net margin for Nektar Therapeutics stands at -1.52. The total capital return value is set at -0.62. Equity return is now at value -189.46, with -40.79 for asset returns.
Based on Nektar Therapeutics (NKTR), the company’s capital structure generated 0.88 points at debt to capital in total, while cash flow to debt ratio is standing at -1.76. The debt to equity ratio resting at 7.3. The interest coverage ratio of the stock is -4.15.
Currently, EBITDA for the company is -86.7 million with net debt to EBITDA at -0.63. When we switch over and look at the enterprise to sales, we see a ratio of 1.93. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
Conclusion
In conclusion, Nektar Therapeutics (NKTR) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
